2015

Our medical news may contain material that is considered promotional and is therefore intended for medical journalists and health care professionals only. By clicking through to see medical news, you are confirming that you are a medical journalist or healthcare professional.

Q3

Press releases
Shionogi receives Marketing and Manufacturing approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia
Press releases
Naldemedine meets primary endpoint in Phase 3 study for the treatment of opioid-induced constipation
Press releases
Shionogi Announces the Continued Expansion of their Operations in Europe with the Launch of Shionogi Italy

Q2

Press releases
Shionogi announces that Naldemedine met the primary endpoint in it's first Japanese phase III study for the treatment of opioid-induced constipation In cancer patients

Q1

Press releases
Shionogi & Co., Ltd announces that Naldemedine meets the primary endpoint in a Phase 3 study for the treatment of opiod-induced constipation
Press releases
Shionogi receives Marketing Authorisation approval for SenshioⓇ (ospemifene) in Europe

Back  number